Skull Base 2011; 21(6): 379-384
DOI: 10.1055/s-0031-1287680
ORIGINAL ARTICLE

© Thieme Medical Publishers

Management of Large and Giant Vestibular Schwannomas

Irumee Pai1 , James Bowman1 , Nick Thomas2 , Neil Kitchen3 , Anthony Strong2 , Rupert Obholzer1 , Michael Gleeson1
  • 1Department of Otolaryngology, Guy's Hospital, London, United Kingdom
  • 2Department of Neurosurgery, King's College Hospital, London, United Kingdom
  • 3Department of Neurosurgery, The National Hospital for Neurology and Neurosurgery, London, United Kingdom
Further Information

Publication History

Publication Date:
14 September 2011 (online)

ABSTRACT

The study was conducted to analyze outcomes following surgical management of large and giant vestibular schwannomas and management options for residual disease. This retrospective case note study includes patients who had undergone microsurgical resection of sporadic, large, or giant vestibular schwannomas from 1986 to 2008. Tumors are classified as large if the largest extracanalicular diameter was 3.5 cm or greater and giant if 4.5 cm or greater. The study included 45 patients (33 large, 12 giant tumors), mean tumor size 4.1 cm. Total excision was achieved in 14 cases (31.1%), near-total in 26 (57.8%), and subtotal in 5 (11.1%). Facial nerve outcome was House-Brackmann Grade I/II in 25 cases (55.6%), III/IV in 16 (35.6%), and V/VI in 4 (8.9%). No recurrence has been detected in those undergoing a complete resection. No residual tumor growth been observed in 15 of 26 who underwent near-total resection (57.7%). Of 11 patients, 10 received further treatment as their residual tumors showed growth. In the subtotal excision group, one patient died, three have demonstrated no growth, and one residual tumor has grown slightly but not required intervention. Optimal management for patients with large or giant vestibular schwannomas has yet to be determined. Management decisions must balance long term function with tumor control.

REFERENCES

  • 1 Nikolopoulos T P, Fortnum H, O'Donoghue G, Baguley D. Acoustic neuroma growth: a systematic review of the evidence.  Otol Neurotol. 2010;  31 (3) 478-485
  • 2 Verma S, Anthony R, Tsai V, Taplin M, Rutka J. Evaluation of cost effectiveness for conservative and active management strategies for acoustic neuroma.  Clin Otolaryngol. 2009;  34 (5) 438-446
  • 3 Solares C A, Panizza B. Vestibular schwannoma: an understanding of growth should influence management decisions.  Otol Neurotol. 2008;  29 (6) 829-834
  • 4 Mandl E S, Meijer O W, Slotman B J, Vandertop W P, Peerdeman S M. Stereotactic radiation therapy for large vestibular schwannomas.  Radiother Oncol. 2010;  95 (1) 94-98
  • 5 Chung W Y, Pan D H, Lee C C et al. Large vestibular schwannomas treated by Gamma Knife surgery: long-term outcomes.  J Neurosurg. 2010;  113 (Suppl) 112-121
  • 6 Kanzaki J, Tos M, Sanna M, Moffat D A, Monsell E M, Berliner K I. New and modified reporting systems from the consensus meeting on systems for reporting results in vestibular schwannoma.  Otol Neurotol. 2003;  24 (4) 642-648 discussion 648-649
  • 7 Godefroy W P, van der Mey A G, de Bruine F T, Hoekstra E R, Malessy M J. Surgery for large vestibular schwannoma: residual tumor and outcome.  Otol Neurotol. 2009;  30 (5) 629-634
  • 8 Ramina R, Coelho Neto M, Bordignon K C, Mattei T, Clemente R, Pires Aguiar P H. Treatment of large and giant residual and recurrent vestibular schwannomas.  Skull Base. 2007;  17 (2) 109-117
  • 9 Park C K, Jung H W, Kim J E, Son Y J, Paek S H, Kim D G. Therapeutic strategy for large vestibular schwannomas.  J Neurooncol. 2006;  77 (2) 167-171
  • 10 Bloch O, Sughrue M E, Kaur R et al. Factors associated with preservation of facial nerve function after surgical resection of vestibular schwannoma.  J Neurooncol. 2011;  102 (2) 281-286
  • 11 Fukuda M, Oishi M, Hiraishi T, Natsumeda M, Fujii Y. Clinicopathological factors related to regrowth of vestibular schwannoma after incomplete resection.  J Neurosurg. 2011;  114 (5) 1224-1231
  • 12 Sughrue M E, Kaur R, Rutkowski M J et al. Extent of resection and the long-term durability of vestibular schwannoma surgery.  J Neurosurg. 2011;  114 (5) 1218-1223
  • 13 Freeman S R, Ramsden R T, Saeed S R et al. Revision surgery for residual or recurrent vestibular schwannoma.  Otol Neurotol. 2007;  28 (8) 1076-1082
  • 14 Pollock B E, Link M J. Vestibular schwannoma radiosurgery after previous surgical resection or stereotactic radiosurgery.  Prog Neurol Surg. 2008;  21 163-168
  • 15 Fuentes S, Arkha Y, Pech-Gourg G, Grisoli F, Dufour H, Régis J. Management of large vestibular schwannomas by combined surgical resection and gamma knife radiosurgery.  Prog Neurol Surg. 2008;  21 79-82
  • 16 Iwai Y, Yamanaka K, Ishiguro T. Surgery combined with radiosurgery of large acoustic neuromas.  Surg Neurol. 2003;  59 (4) 283-289 discussion 289-291
  • 17 O'Reilly B F, Kishore A, Crowther J A, Smith C. Correlation of growth factor receptor expression with clinical growth in vestibular schwannomas.  Otol Neurotol. 2004;  25 (5) 791-796
  • 18 Cafer S, Bayramoglu I, Uzum N, Yilmaz M, Memis L, Uygur K. Expression and clinical significance of Ki-67, oestrogen and progesterone receptors in acoustic neuroma.  J Laryngol Otol. 2008;  122 (2) 125-127

Rupert Obholzer M.A. (Oxon) F.R.C.S. (ORL-HNS). 

Department of Ear, Nose, and Throat, Guys Hospital

Great Maze Pond, London SE1 9RT, United Kingdom

Email: rupertobholzer@nhs.net

    >